Kiniksa details Phase 2/3 trial design for KPL-387 in recurrent pericarditis; initiation mid-2025

Kiniksa Pharmaceuticals International, plc

Phase 2/3 trial: dose-focusing portion enrolls up to ~80 patients; pivotal portion up to ~85.
Primary endpoint: time to treatment response at Week 24 (Phase 2) and time to first recurrence (Phase 3).
Phase 1 single ascending dose data support monthly subcutaneous dosing with liquid formulation.
Phase 2 data expected in second half of 2026.
Corporate presentation at Jefferies 2025 Global Healthcare Conference at 12:50 pm ET on June 5.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.